CS
AKYA

Credit Suisse’s Akoya BioSciences AKYA Stock Holding History

Credit Suisse’s Portfolio AKYA Stock Details AKYA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-1
Closed -$10 – 3272
2022
Q4 		$10 Sell
1
-87
-99% -$1.07K ﹤0.01% 3733
2022
Q3 		$1K Buy
88
+68
+340% +$896 ﹤0.01% 3798
2022
Q2 		$0 Buy
+20
New +$207 ﹤0.01% 3891

Other funds holding AKYA

BWLSA
Blue Water Life Science Advisors Larkspur, California $125M AUM 91.82% 1-Year Est. Return
HEC
Hudson Executive Capital New York $151M AUM 60.14% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BOTOTLSJU
Board of Trustees of The Leland Stanford Junior University Redwood City, California $849M AUM 55.45% 1-Year Est. Return
GIM
Granahan Investment Management Waltham, Massachusetts $2.07B AUM 56.45% 1-Year Est. Return
ACM
Altium Capital Management New York $42M AUM
SW
SVB Wealth Boston, Massachusetts $1.59B AUM 24.57% 1-Year Est. Return
UIC
Uniplan Investment Counsel Milwaukee, Wisconsin $974M AUM 21.37% 1-Year Est. Return

Credit Suisse's AKYA Position: Q1 2023 in Review

Credit Suisse sold out of Akoya BioSciences (AKYA) in Q1 2023, closing a stake of 1 share — an estimated $10 sold.

Credit Suisse first reported a position in AKYA in Q2 2022 and held it in 3 quarters. The position peaked at $1K in Q3 2022. 63 funds tracked by Wall St. Rank hold AKYA as of Q1 2023.

  • Credit Suisse reported no remaining Akoya BioSciences position as of Q1 2023 after selling out during the quarter.
  • Credit Suisse sold 1 Akoya BioSciences share in Q1 2023, an estimated $10.
  • Credit Suisse first reported a position in Akoya BioSciences in Q2 2022 and held it in 3 quarters.
  • Credit Suisse's Akoya BioSciences position peaked at $1K in Q3 2022.
  • 63 funds tracked by Wall St. Rank held Akoya BioSciences as of Q1 2023.

Based on Credit Suisse's 13F filing for Q1 2023, filed 10 May 2023.